AbbVie stock builds on Q2 2026 growth as immunology and neuroscience drive earnings
Published on 08/24/2026 at 08:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (US00287Y1091) stock is underpinned by solid second-quarter 2026 earnings, with net revenue rising 10.2% year over year to $16.990 billion and adjusted diluted EPS advancing 22.9% to $3.65. As of August 23, 2026, recent market data show the shares trading in the mid-$260s, providing investors with a large-cap healthcare name that combines growth in newer therapies with a sizable dividend.
Q2 2026 earnings show double-digit growth
According to a Q2 2026 earnings overview covering AbbVie results, the company reported net revenue of $16.990 billion for the quarter, up 10.2% compared with the same period a year earlier. GAAP diluted EPS increased from $0.52 in the prior-year quarter to $2.03, while adjusted diluted EPS climbed 22.9% to $3.65, highlighting the underlying earnings momentum.
The same Q2 2026 summary notes that immunology revenue grew 15.1% year over year as newer drugs Skyrizi and Rinvoq more than offset declines in legacy blockbuster Humira. Neuroscience revenue advanced 20.3%, contributing to the diversified earnings base and helping AbbVie generate growth beyond its traditional immunology franchise.
An in-depth article on AbbVie’s strategy analyzing recent results details how Skyrizi revenue increased 24.4% to $5.51 billion in the quarter, while Rinvoq revenue rose 24.5% to $2.53 billion. Together, these two medicines generated more than $8 billion in sales during Q2 2026, compared with $756 million from Humira, illustrating the shift in AbbVie’s revenue mix.
That same analysis points out that total immunology revenue reached $8.79 billion in Q2 2026, up 15.1% despite Humira sales falling 35.9%. The performance of Skyrizi and Rinvoq thus more than compensated for the erosion of Humira following the loss of exclusivity, a key concern for investors watching AbbVie’s transition away from its historical flagship product.
Guidance, acquisition plans and dividend support outlook
The Q2 2026 earnings commentary covering AbbVie guidance notes that the company lowered full-year adjusted EPS guidance to a range of $13.87 to $14.07. The adjustment primarily reflects anticipated dilution from the proposed $10.9 billion acquisition of Apogee Therapeutics, rather than weakness in AbbVie’s existing operations, signaling that management is willing to invest in pipeline expansion while maintaining healthy earnings power.
The longer-form Q2 2026 discussion reviewing guidance changes confirms that the revised EPS range of $13.87 to $14.07 replaces a previous range of $13.91 to $14.11. While the numerical reduction is modest, the inclusion of expected deal dilution adds financial and execution risk that investors must weigh against the strategic benefits of enhancing AbbVie’s immunology and dermatology pipeline.
A broader valuation and dividend-focused article highlighting large-cap dividend names states that AbbVie posted Q2 2026 revenue of nearly $17 billion, broadly matching the $16.990 billion figure reported in the earnings summary, with Skyrizi at $5.5 billion (up 24%) and Rinvoq above $2.5 billion (up 23.7%). The same piece reiterates that management raised full-year EPS guidance to the $13.87 to $14.07 range and notes that one firm increased its price target on AbbVie to $303, with Wall Street consensus targets clustered in the mid-$270s.
In that dividend-focused overview, AbbVie’s annualized dividend is cited at $6.92 per share, reflecting a quarterly payout that has risen from $1.64 in 2025 to $1.73 by August 2026. Another article on income strategies discussing dividend stocks notes that AbbVie stock pays a dividend of $1.73 per share at a yield of 2.6%, which is higher than that of a major healthcare peer. For investors, the combination of double-digit EPS growth and an increasing dividend is an important part of the equity story.
Consensus data referenced in a recent institutional holding update summarizing rating trends indicates that AbbVie currently carries an average rating described as a moderate buy, with an average target price reported in the mid-$270s. Another institutional flow note covering recent share purchases cites a similar consensus target range, suggesting that analysts broadly expect continued earnings growth and dividend support, though with some dispersion in upside views.
Skyrizi and Rinvoq anchor AbbVie’s growth engine
The detailed Q2 2026 breakdown reviewing product performance underscores that Skyrizi and Rinvoq are now AbbVie’s primary growth drivers in immunology. Skyrizi’s 24.4% revenue increase to $5.51 billion and Rinvoq’s 24.5% rise to $2.53 billion together produced more than $8 billion in quarterly sales, materially exceeding Humira’s $756 million contribution during Q2 2026.
For context, that same source shows Humira sales declining 35.9% year over year as biosimilar competition spreads, yet total immunology revenue grew 15.1% to $8.79 billion because Skyrizi and Rinvoq expanded rapidly. The numbers indicate that AbbVie’s replacement strategy for Humira is not only working but generating net growth in its core therapeutic area, a key reassurance point for long-term shareholders.
Beyond immunology, the Q2 2026 earnings coverage summarizing segment trends reports that neuroscience revenue advanced 20.3% over the prior year. This segment growth supports AbbVie’s diversification into areas such as migraine and neurodegenerative conditions and helps balance the portfolio as management invests in new indications and mechanisms of action.
From a profitability perspective, the same Q2 2026 summary notes that GAAP results benefited from lower acquired in-process research and development, reduced contingent consideration expense, and more favorable tax costs. Together with rising adjusted EPS, these factors suggest that AbbVie is managing its expense base efficiently, even while funding pipeline development and strategic deals like the planned Apogee Therapeutics acquisition.
Representative product Skyrizi extends immunology reach
One representative product within AbbVie’s portfolio is Skyrizi, an immunology therapy that has become central to the company’s growth narrative. In Q2 2026, Skyrizi generated $5.51 billion in revenue, increasing 24.4% year over year as highlighted in the detailed Q2 results analysis covering drug-level performance. With more than $5 billion in quarterly sales, Skyrizi’s contribution alone accounts for a significant share of AbbVie’s total immunology revenue.
The same report indicates that Skyrizi, together with Rinvoq, produced more than $8 billion in combined sales in Q2 2026, sharply ahead of the $756 million booked from Humira in the period. This comparison demonstrates how Skyrizi’s expansion into various immunology indications, alongside Rinvoq, has helped AbbVie navigate the transition away from Humira exclusivity and sustain overall revenue growth.
AbbVie stock and market context
Recent market data summarized in an institutional ownership update including a price reference show AbbVie shares opening at $265.62 on August 21, 2026. With consensus analyst targets reported in the mid-$270s in the same source set, the shares are trading only a few dollars below average expectations, suggesting that much of the near-term earnings and dividend story may already be reflected in the valuation, while further upside would likely depend on continued execution in immunology and successful integration of new pipeline assets.
Another valuation-focused overview discussing pricing and earnings multiples observes that the revised EPS guidance range of $13.87 to $14.07 for full-year 2026, combined with a share-price scenario in the low $300s, would imply a forward price-to-earnings multiple in the low 20s. While that specific scenario reflects one contributor’s assumption rather than current pricing, it illustrates how investors may weigh AbbVie’s double-digit earnings growth against broader market valuation levels when considering long-term positioning.
For income-oriented investors, the dividend remains a central pillar of AbbVie’s equity case. As noted in the dividend-focused article reviewing dividend yields, the stock pays $1.73 per share each quarter, implying $6.92 in annualized dividends and a yield of 2.6% based on recent prices. With the quarterly payout up from $1.64 in 2025 to $1.73 by August 2026, the steady increase in cash returns complements AbbVie’s earnings growth and supports its reputation as a long-term healthcare income holding.
Go deeper
More on AbbVie stock and its evolving earnings profile appears in the Q2 2026 earnings discussions and product-level analyses available from the cited sources, which show how immunology and neuroscience segments are reshaping the company’s revenue mix.
Investor Relations
Further details on AbbVie Inc. can be found via its corporate investor relations materials, including presentations and filings that elaborate on pipeline development, segment performance, and capital-allocation priorities.
Fact box
Company: AbbVie Inc.
ISIN: US00287Y1091
Ticker: ABBV
Exchange: NYSE
Market cap: Large-cap biopharmaceutical company, supported by double-digit Q2 2026 revenue and EPS growth
Sector / Industry: Health care / Pharmaceuticals and biotechnology
Index membership: Constituent of major US equity indices tracking large-cap health care stocks
